Search results
Author(s):
Christie Ballantyne
Added:
1 year ago
ACC.23/WCC—We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C)…
View more
Author(s):
Frederick Raal
Added:
7 months ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104).
The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in…
View more
Author(s):
Shane Prejean
,
Todd M Brown
Added:
3 years ago
Proprotein convertases are proteolytic enzymes that activate proteins by post-translational alterations in protein structure. Proprotein convertase subtilisin/kexin 9 (PCSK9) is a proprotein convertase that binds and inactivates the low-density lipoprotein (LDL) receptor on the surface of hepatocytes resulting in higher levels of serum LDL cholesterol (LDL-C).1 Over-expression of PCSK9 leads to a…
View more
Pedro Mata
Author
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
Prof Nicolas Van Mieghem and Dr Joost Daemen interprets the findings from the top 10 ACC.23/WCC late-breaking and featured science trials and studies in their critical View from the Thoraxcenter review series. Join them as they consider the implications for research and offer an insight into how they will incorporate the latest data into their day-to-day clinical practice.
What are the top…
View more
Added:
3 years ago
Robert Rosenson (Mount Sinai, New York, US) discusses the safety and efficacy results of Evinacumab, an investigational fully-human monoclonal antibody that binds to and blocks the function of ANGPTL3, in patients with homozygous familial hypercholesterolemia (HoFH).
Questions:
1. What is the background of this trial?
2. What are the objectives of this trial?
3. What were the eligibility…
View more
Author(s):
Daniel J Pelchovitz
,
Robert L Wilensky
Added:
3 years ago
Vasa vasora are the blood supply of the artery itself, originating in the adventitia in response to the arterial wall’s nutritional requirements. The presence of a thicker tunica media or neointima requires the development of vasa vasorum to meet the metabolic demands of the arterial wall, since diffusion from the arterial lumen alone is insufficient. Over 40 years ago Wolinsky and Glagov…
View more
Author(s):
Yugo Yamashita
Added:
8 months ago
What's hot at the European Society of Cardiology (ESC) Congress 2023?
Browse our curated coverage of the latest updates in cardiology from Amsterdam.
Watch ourView From the Thoraxcenterseries for a concise line up of the most awaited trials fromProf Nicolas Van MieghemandDr Joost Daemen.
For a deeper dive into key clinical trial data and its applicability, host,Dr Harriette Van…
View more
Author(s):
Edward T Carreras
,
Donna M Polk
Added:
3 years ago
Cardiovascular disease affects more than one-third of American adults and is the leading cause of mortality in the United States and worldwide.1 Only 4.5 % of those over the age of 20 meet the ideal levels of the seven metrics of cardiovascular health including cholesterol levels.1 Of modifiable risk factors, including smoking, hypertension, diabetes, and obesity, dyslipidemia has been shown to…
View more
Author(s):
Hiroyuki Daida
,
Saahil A Jumkhawala
Added:
1 year ago
AHA 22 - CardioNerds Fellow, Dr Saahil A Jumkhawala (Rutgers New Jersey Medical School, US) joins us in this collaboration between the@CardioNerdsand Radcliffe Cardiology to interviewProf Hiroyuki Daida (Juntendo Graduate School of Medicine, JP) investigator of the RESPECT EPA trial.
This randomized phase 4 trial looked at Japanese participants to assess whether long-term use of icosapent ethyl…
View more